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http://dx.doi.org/10.1016/j.hkjn.201Summary Background: Previous studies have shown that up to 40% of childhood-onset min-
imal-change nephropathy (MCN) cases persist after puberty. However, data are scarce con-
cerning the long-term renal prognosis and prevalence of treatment-related complications of
this group of patients after they become adults.
Materials and methods: The clinical records of 55 consecutive pediatric patients with biopsy-
proven MCN treated in our hospital from 1984 to 2004 were reviewed to evaluate the disease
pattern, treatment regimen, and the development of treatment-related complications.
Results: Of the 55 patients treated, 35 were followed after age 18 years; 13 (37%) had relapses
during adulthood. Treatment-related complications were observed in 20 patients (57%),
including being overweight (23%), impaired fasting glucose (14%), infertility (14%), persistent
low grade proteinuria (11%), fracture (9%), and hypertension (9%). All patients had normal
renal function when last assessed.
Conclusion: A substantial proportion of patients with childhood-onset MCN continued to have
relapse after they became adults. Although almost all patients have normal renal function, pro-
longed use of steroid and immunosuppressive agents results in a considerable risk of treatment-
related complications. Life-long follow-up seems advisable for this group of patients, not only
for detecting relapses, but also to allow timely diagnosis of treatment-related complications.
背景：之前的研究顯示，童年病發的微小變化型腎病變(MCN)有高達40%會持續至青春期之後；然
而，對於這類病情延續至成年的患者，至今少有研究對其長期腎臟預後及治療相關併發症比率作
出報告。
方法：針對經活檢證實的MCN兒童患者，我們回顧了55位於1984至2004在本院接受治療的連續個
案，從而對其病情發展、治療用藥、及治療相關併發症作出瞭解。
結果：在所有55位兒童病人中，35人持續接受追蹤至成年期。在成年階段中，13人(37%)出現復
發，20人(57%)發生治療相關併發症，後者包括過重(23%)、空腹血糖過高(14%)、不孕症(14%)、持
續性輕度蛋白尿(11%)、骨折(9%)、及高血壓(9%)。在最後追蹤中，所有人均呈現正常的腎功能。of Medicine & Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New
.hk (C.-C. Szeto).
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Childhood minimal-change nephropathy 23結論：不少的童年病發MCN患者會在成年期復發，即使幾乎所有人的腎功能正常，持續使用的類
固醇及免疫抑制劑所導致的治療相關併發症風險卻不容忽視。對於這些病人，似乎應予以終生的
追蹤，以利於病情復發及治療相關併發症的及早發現。Introduction
Minimal change nephropathy (MCN) is the major cause of
steroid-sensitive nephrotic syndrome in childhood.1 It was
previously believed that MCN runs a benign course in
childhood, and most cases remit prior to or at puberty.2
However, more recent studies have revealed a higher rate
of disease relapse during adulthood despite the availability
of more potent immunosuppressive agents.1,3 More impor-
tantly, a prolonged course of the disease implies that pa-
tients are exposed to high cumulative doses of
corticosteroid and, sometimes, other immunosuppressive
agents, and the risk of developing adverse effects increase
correspondingly. Although there have been many studies on
the disease course and treatment response in children
suffering from steroid sensitive nephrotic syndrome or
MCN, few studies have explored the outcome when those
children reach adulthood. Even in the largest series by the
International Study of Kidney Disease in Children (ISKDC),4
where 389 biopsy-proven children with MCN were fol-
lowed for up to 17.6 years, no data were provided on those
patients who were continued to be followed after puberty.
Since cyclosporine was introduced in the late 1960s, the
outcome of MCN patients with frequent relapse changed
dramatically. In addition to the availability of cyclosporine to
our therapeutic armamentarium, there have been many
concomitant changes in the clinical nephrology practice
during this period. In the past decade, a few case series re-
ported the clinical course of adult western patients who had
childhood-onset MCN.1,3,5 The overall rate of relapses during
adulthood ranges from 29% to 42%. In the study by Fakhouri
et al,1more than40%ofpatientswere identifiedasadulthood
relapsers, one-third of the patients relapsed during adult-
hood in the report by Ru¨th et al,3 whereas 29% patients in the
study by Kyrieleis et al relapsed as adults.5 In the present
study, we evaluate the long-term outcome of Chinese chil-
dren with biopsy-proven MCN after they became adults.
Materials and methods
There were 55 pediatric patients (age < 18 years) identified
with biopsy-proven MCN treated in our hospital from 1984
to 2004. Out of the 55 patients, 35 were followed after age
18 years. The clinical records of these patients were
reviewed; relevant data on the course of disease, treat-
ment regimen and response, disease outcome, as well as
complications were collected.
Treatment protocol
The standard regimen in our hospital for the initial episode
of nephrotic syndrome diagnosed in childhood was similar
to that outlined by international guideline,6 and was
generally prednisolone, at a starting dose of 60 mg/m2. Thisregimen was continued and tapered in 8e12 weeks when
proteinuria disappeared. Further relapses were treated
with repeated high doses of prednisolone until proteinuria
subsided. In patients with frequent relapses or those
dependent on steroid or in those with substantial steroid-
related adverse effects, second line agents such as cyclo-
phosphamide, cyclosporine, or levamisole were used.
Definitions
The definitions of treatment response have been previously
described.5 Briefly, complete remission of nephrotic syn-
drome is defined as: a reduction in urinary protein excre-
tion rate to <4 mg/m2/hour; proteinuria <0.2 g/10 mM
creatinine; or zero to trace albuminuria on dipstick for 3
consecutive days. Partial remission is defined as protein
excretion between 0.2 g/10 mM and 2 g/10 mM creatinine
without hypoalbuminemia. A relapse-free period of a min-
imum of 2 years without immunosuppressive medication is
defined as a permanent remission. Patients were classified
as frequent relapsers when they experienced four or more
relapses within a 12-month period.
Complications
The long-term complications of nephrotic syndrome and
immunosuppressive medications were also reviewed. Pa-
rameters reviewed include renal function, short stature,
being overweight or obese, osteoporosis, hypertension,
ocular complications, and fertility. Short stature was
defined as a height less than 2.5 standard deviation
compared with normal stature for age and gender in the
local population. Overweight was defined as a body mass
index > 23 kg/m2; obesity was defined as a body mass
index > 26 kg/m2.7 Hypertension was defined as an office
blood pressure of over 140/90 mmHg or the need of anti-
hypertensive treatment.8
Statistical analysis
Statistical analysis was performed by SPSS for Windows
software version 17.0 (SPSS Inc, Chicago, IL, USA). Data are
expressed as mean  standard deviation if normally
distributed, or median (range) if not. Groups were
compared by unpaired Student t test, Chi-square test, or
Fisher’s exact test as appropriate. A p-value of <0.05 was
considered significant. All probabilities are two-tailed.
Results
Clinical features
Of the 55 patients identified, 35 were followed into adult-
hood. Their average age at presentation was 8.8  3.2
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indications of renal biopsy were atypical clinical features (9
cases), frequent relapses (18 cases), steroid dependent (7
cases) and steroid resistant nephrotic nephrotic syndrome
(1 case). Six of the 35 patients actually had a second renal
biopsy for frequent relapses or steroid dependency; all
repeat renal biopsies confirmed the diagnosis of MCN, and
none had significant tubulointerstitial scarring.
Among the 35 patients who were followed until adult-
hood, the median follow-up period since initial diagnosis
was 16 years (range, 8e29 years). The median age at the
time of last follow-up was 25 years (range, 18e43 years). Of
these 35 patients, 13 (37%) had at least one flare after age
18 years; nine were actually frequent relapsers as adults,
and six progressed to become steroid dependent. In addi-
tion, one patient who did not have a relapse as an adult was
steroid dependent for refractory pemphigus vulgaris
instead of nephrotic syndrome.
The clinical characteristics of patients who had and did
not have a relapse in adulthood are compared and sum-
marized in Table 1. In short, there was no significant dif-
ference in baseline clinical characteristics or indications for
renal biopsy between patients who had and did not have a
relapse as an adult. As expected, patients who had relapses
after becoming an adult were more likely to require
treatment with cyclophosphamide and/or cyclosporine A
than those who did not flare after adulthood (see Table 1).
By contrast, the incidence of being treated with levamisole
was similar.Table 1 Clinical characteristics of patients.
Relapse as
adult
No relapse
as adult
No. of patients 13 22
Sex (M:F) 11:2 14:8
Age (y)
At diagnosis 9 (3e14) 9.5 (2e13)
At last flare 22 (18e39) 13 (5e17)
At last follow-up 24 (20e43) 25 (19e41)
Feature at presentation
Proteinuria (g/d) 3.94  1.11 3.77  1.53
Serum creatinine (mM) 54.5  20.8 54.4  16.7
Microscopic hematuria, n 2 7
High blood pressure, n 0 1
Concomitant conditions, n
HBsAg carrier 1 3
Eczema 1 1
Asthma 1 2
Allergic rhinitis 1 1
Indications for renal biopsy, n
Frequent relapses 8 10
Steroid dependent 3 4
Steroid resistant 0 1
Atypical features 2 7
Second line agents, n
Cyclophosphamide 5 2
Cyclosporine A 8 2
Levamisole 2 3
Duration of follow-up (y) 17 (9e28) 16 (8e28)Overview of treatment complications
Of the 35 patients, 20 (57.1%) had at least one treatment-
related complication. In addition, two patients had epi-
lepsy, one had steroid dependent pemphigus vulgaris (see
above), one had thyrotoxicosis, one developed Guillain-
Barre´ syndrome, and one developed scleroderma during
follow-up.
The incidences of treatment-related complications were
compared between patients who had and did not have
relapse of nephrotic syndrome during adulthood and are
summarized in Table 2. There was no significant difference
in the incidence of any treatment-related complication
between the groups, although the numbers of specific
complication were small.
Growth and development
Specific clinical factors that may be related to specific
treatment complications were further explored. Of the 35
patients, two had short stature, eight (22.9%) were over-
weight, and six (17.1%) had impaired fasting glucose or
diabetes. Among the eight overweight patients, seven were
male, three had frequent relapses at adulthood, and
another required long-term steroid for pemphigus vulgaris
(see above). Four of them had impaired fasting glucose,
and one had overt diabetes. Among the six patients who
had impaired fasting glucose or diabetes, five were over-
weight, and three required repeated courses of cortico-
steroid therapy.
Five patients (14.3%) in this review reported fertility
problem in adulthood; two were male. Two patients were
frequent relapsers in adulthood. Contrary to the general
expectation, only one had been treated with cyclophos-
phamide, whereas two had received cyclosporine A.
Infection and malignancy
Major infection was reported in four patients (11.6%). Two
patients had tuberculosis, and two had a flare-up of chronicTable 2 Complications of treatment.
Relapse
as adult
No relapse
as adult
No. of cases 13 22
Any complication, n 7 13
Short stature 1 1
Overweight 3 5
Impaired fasting glucose 2 3
Diabetes 0 1
Fertility problem 3 2
Any fracture 1 2
Peptic ulcer 0 1
Cataract 1 1
Any cancer 0 2
Tuberculosis 1 1
Hepatitis B flare 1 1
Hypertension 2 1
Persistent proteinuria 1 3
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cyclophosphamide and/or cyclosporine A therapy. Contrary
to general expectations, none of the patient in our series
had herpes zoster reactivation or bacterial peritonitis.
Two patients (5.8%) had malignancy; both were female.
One had ovarian carcinoma whereas the other had malig-
nant neuroma. Neither patient had flare-up of nephrotic
syndrome in adulthood, and neither had received cyclo-
phosphamide or cyclosporine A.
Other steroid-related complications
Two patients (5.7%) had cataracts; one was a frequent
relapser. Contrary to general expectations, none of the
patients in this review had avascular necrosis of hip. How-
ever, three patients (8.6%) had a history of bone fracture;
two of them received long-term steroid treatment. All
three fractures were reported to be the result of appar-
ently minor trauma and were at unconventional sites (1
humerus, 1 radius, and 1 metatarsal). None of the patients
in this series had overt cardiovascular disease, venous
thromboembolism, or mood disturbance.
Renal outcome
All patients in this series had normal serum creatinine at
their last follow-up. The mean creatinine was
70.3  15.2 mM. Serum creatinine levels at the last follow
up were 68.4  14.7 mM and 71.7  15.9 mM for patients who
had and did not have relapse in adulthood, respectively
(p Z 0.6). Persistent low grade proteinuria, however, was
noted in four patients (11.4%); only one was a frequent
relapser, was overweight, and had impaired fasting
glucose.
Three patients (8.6%) developed hypertension; two of
those were frequent relapsers, and were also overweight
and had impaired fasting glucose. All these patients had a
history of being treated with cyclosporine A; two had also
been treated with cyclophosphamide.
Discussion
In this study, we reviewed the clinical course of a large
cohort of patients with childhood onset biopsy-proven MCN.
The incidence of relapse in adulthood is similar between
our patients and the previous reports.1,3,5 It is important,
however, to note that renal biopsy was only performed in
our center for pediatric patients with nephrotic syndrome if
there was a suboptimal response to empirical steroid
treatment, when the disease was steroid-resistant (and
hence when second-line treatment, such as cytotoxic
agent, was considered), or when there were atypical clin-
ical features during presentation. This policy may lead to a
selection bias of more severe cases in our study, which
explains the generally high risk of relapse as adults.
Although most children with MCN have a good initial
response to corticosteroid treatment, a significant propor-
tion of children experience relapse, and some gradually
become steroid-dependent.9 Previous studies as well as our
present review show that a considerable proportion of
these children continue to relapse after they become adultsrequiring cytotoxic treatment. For example, the proportion
of patients with childhood MCN and require cytotoxic
therapy was reported to be 49% in Lewis et al’s study,10 57%
in Ru¨th et al’s study,3 72% in Fakhouri et al’s study,1 and 34%
in our present series.
Long-term corticosteroid treatment is well-known to be
associated with many systemic side effects. In the present
series, steroid-related side effects account for most of the
complications identified. Notably, being overweight (22.9%)
and glucose intolerant (17.1%) topped our list of compli-
cations. By contrast, short stature (5.7%) and cataract
(5.7%) are much less frequent than expected. In general,
our observations are similar to previous reports. For
example, in Fakhouri et al’s study,1 steroid-related side
effects also topped the complications list, with 44% of pa-
tients who suffered from growth retardation, diabetes,
hypertension, osteoporosis, or cardiovascular diseases.
Contrary to the general belief, short stature, and obesity
were relatively uncommon complications in the studies by
Fakhouri et al1 and Ru¨th et al,3 and our present study. In
fact, impairment of longitudinal growth was not observed
in Kyrieleis et al’s series.5 In the report of Ru¨th et al3 as well
as our own study, significant difference was not found in
the risk of obesity or short stature between adult relapsers
and non-relapsers. This favorable risk profile in terms of
growth and development may be related to the judicious
use of corticosteroid by most pediatricians and the liberal
use of steroid-sparing regimens once there are early signs
of growth-related complications, so much so that the final
adult height and weight did not differ much from the
normal population.
Osteoporosis and avascular necrosis of the hip are both
well-known complications related to prolonged steroid use
in adults.11 For example, Hegarty et al12 reported that in 34
patients who had biopsy-proven childhood onset MCN and
were investigated for their bone mineral density (BMD), a
substantial decrease in the distal radial trabecular volu-
metric BMD was found (mean Z score, 0.95), although the
total volumetric BMD Z score was not decreased. In this
study, there were also less dramatic reduction in the mean
T scores of lumbar spine and femoral neck (0.45 and
0.49, respectively).12 Similarly, Gulati et al13 reported
that an alarming proportion of children with nephrotic
syndrome was found to be either osteopenic (61%) or
osteoporotic (22%) on dual-energy x-ray absorptiometry
study of the spine, although this study does not have a
control group for comparison. By contrast, it is interesting
to note that Leonard et al14 found that intermittent high-
dose corticosteroid treatment was not associated with
significant deficits in the bone mineral content of the spine
of 60 children. In our present study, bone mineral density
was not formally measured. Nonetheless, bone-related
complications occurred in 8.6% of the patientsdall had
fractures after minor trauma and none had avascular ne-
crosis of the femoral head. More importantly, this number
of bone related complications is likely to be under-
estimated because the median age of our patients at
evaluation was 25 years, while bone-related complications
usually develop after the third decade of life (i.e. after
passing the physiological peak of BMD). It has been rec-
ommended that adult patients who received long-term or
repeated high-dose corticosteroid treatment should receive
26 V.W.-K. Kwong et al.bisphosphonates for the prevention of osteoporosis.15
However, similar recommendations are not available for
children, further studies on this area is necessary.
Infections are a major cause of morbidity and mortality
in children suffering from nephrotic syndrome. Both the
nephrotic state itself and the use of immunosuppressive
treatments increase the risk of various infections. For
example, Ru¨th et al3 reported that 14% pediatric patients
with nephrotic syndrome had various severe infections,
including septicemia, pneumococcal peritonitis, and herpes
zoster. Similarly, in the ISKDC report,9 10 of the 389 chil-
dren died and six were due to infections (three had septi-
cemia, two had spontaneous bacterial peritonitis, and one
had pancreatitis with secondary peritonitis). A prolonged
course of corticosteroid treatment and the use of second
line immunosuppressive agents were major risk factors of
infection-related mortality; five of the six patients who
died had steroid-resistant nephrotic syndrome, and three
had received cyclophosphamide as part of their treatment.9
Another important infection to be considered is hepatitis
B, which is endemic in our locality, and hepatitis flare in
nephrotic patients with who are hepatitis B carriers is al-
ways a concern. In the present study, four patients were
hepatitis B carrier, and two had hepatitis flare. Both pa-
tients received prolonged courses of corticosteroid treat-
ment, together with the use of potent immunosuppressive
agents (cyclophosphamide and cyclosporine). Traditionally,
it is believed that the risk of hepatitis B flare is especially
high during the period of dosage reduction of the immu-
nosuppressants. However, both of the patients of our series
had hepatitis flare during the phase of high dose immuno-
suppressive therapy. Nonetheless, it is also important to
note that these patients were treated in the 1990s when
antiviral prophylaxis was not available.
In this review, none of our patients had cardiovascular
disease, which is another important complication related to
long-term steroid use in adult patients. This is probably
because our patients are relatively young (mean age at
analysis was 25 years). As mentioned above, a substantial
proportion of our patients were overweight, or had hyper-
tension, glucose intolerance, or diabetesdall traditional
risk factors for cardiovascular disease development. It
seems likely that some cardiovascular events would
develop in our patients if they are continued to be followed
for another 10 years or 15 years.
Despite a high percentage of patients who relapsed in their
adulthood, the long-term renal prognosis is good. In the pre-
vious studies by Ru¨th et al3 and Kyrieleis et al,5 as well as the
present study, all patients had normal renal function at the
endof theobservationperiod.The renalprognosis is goodeven
in patients with steroid-dependent and frequently relapsing
disease treated with cyclophosphamide and cyclosporine.5 By
contrast, Fakhouri et al1 reported that one patient who
required a prolonged course of cyclosporine A therapy for
steroid dependent MCN developed end stage renal failure,
which was presumably the result of chronic calcineurin in-
hibitor nephrotoxicity. Long-term cyclosporine A treatment is
also well known to be associated with the development of
hypertension. Indeed,all threepatientswhohadhypertension
in our study had a history of cyclosporine use.
There are a number of inadequacies of our study. First,
the number of patient is small, and a reliable estimation onthe incidence of specific treatment-related complications is
not possible. Furthermore, this is a retrospective review of
hospital and computer records, and we did not actively
screen for the presence of many complications. Nonethe-
less, nearly all patients had records of body weight, height,
renal function, urinalysis, and fasting glucose level checked
during follow up. We believe that the incidence of being
overweight and glucose intolerant in our study should be
reasonably reliable. Second, many of our patients were
treated over 10 years or even 20 years ago, and their clin-
ical behavior, including rate of relapse and incidence of
complication, may not reflect that of the contemporary
practice. Although the use of corticosteroid and cyclo-
phosphamide for the treatment of MCN changed very little
after the publication of the ISKDC study in 1981,4 cyclo-
sporine A was only commonly used as a second line agent
after mid-1990s, and the therapeutic armamentarium
available for the treatment and prevention of infection has
expanded considerably in the past 2 decades. We should be
cautious when extrapolating the result of this review (as
well as other published studies in this area) to patients we
are taking care of nowadays.
In conclusion, we found that a substantial proportion of
patients with childhood-onset MCV continued to have re-
lapses after they became adults. Although most, if not all,
patients have normal renal function, the prolonged use of
steroid and second line immunosuppressive agents results
in a considerable risk of extra-renal complications, such as
infections, being overweight, diabetes, hypertension, bone
fracture, growth retardation, infertility, and possibly ma-
lignancy. Strategies should be developed to ensure the
judicious use of these potentially toxic treatments. Life-
long follow-up seems advisable for this group of patients,
not only for detecting relapses, but also to allow timely
diagnosis of treatment related complications.
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